CA2336150A1 - 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines en tant que ligands specifiques du sous-type du recepteur de la dopamine - Google Patents

1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines en tant que ligands specifiques du sous-type du recepteur de la dopamine Download PDF

Info

Publication number
CA2336150A1
CA2336150A1 CA002336150A CA2336150A CA2336150A1 CA 2336150 A1 CA2336150 A1 CA 2336150A1 CA 002336150 A CA002336150 A CA 002336150A CA 2336150 A CA2336150 A CA 2336150A CA 2336150 A1 CA2336150 A1 CA 2336150A1
Authority
CA
Canada
Prior art keywords
alkyl
hydrogen
compound according
halogen
benzothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002336150A
Other languages
English (en)
Inventor
Xi Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2336150A1 publication Critical patent/CA2336150A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention concerne des composés de la formule (A) ou des sels d'addition acides pharmaceutiquement acceptables desdits composés. Dans ladite formule, R¿1? et R¿2? sont identiques ou différents et représentent hydrogène, halogène, alkyle C¿1?-C¿6?, alcoxy C¿1?-C¿6?, alkylthio C¿1?-C¿6?, hydroxy, amino, mono ou dialkylamino(C¿1?-C¿6?), cyano ou trifluorométhyle; Ar est aryle ou hétéroaryle, chacun étant éventuellement substitué par R¿3?, R¿4? et/ou R¿6?; R¿3?, R¿4? et R¿6? sont, indépendamment, hydrogène, halogène, hydroxy, alkyle C¿1?-C¿6?, alcoxy C¿1?-C¿6?, perfluoro-alkyle C¿1?-C¿6?, perfluoro-alcoxy C¿1?-C¿6?, ou SO¿2?NH¿2?; ou R¿3? et R¿4? forment ensemble, avec les atomes auxquels ils sont liés, un noyau de 5 à 7 atomes; et R¿5? est hydrogène ou alkyle C¿1?-C¿6?. Ces composés sont utiles pour le traitement et/ou la prévention de troubles neuropsychologiques, y compris, entre autres, la schizophrénie, la manie, la démence, la dépression, l'anxiété, le comportement compulsif, l'abus de substances psychoactives, les troubles moteurs apparentés à la maladie de Parkinson et les troubles moteurs associés à l'usage de neuroleptiques antipsychotiques.
CA002336150A 1998-06-30 1999-06-25 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines en tant que ligands specifiques du sous-type du recepteur de la dopamine Abandoned CA2336150A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10760798A 1998-06-30 1998-06-30
US09/107,607 1998-06-30
PCT/US1999/014427 WO2000000482A1 (fr) 1998-06-30 1999-06-25 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines en tant que ligands specifiques du sous-type du recepteur de la dopamine

Publications (1)

Publication Number Publication Date
CA2336150A1 true CA2336150A1 (fr) 2000-01-06

Family

ID=22317462

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002336150A Abandoned CA2336150A1 (fr) 1998-06-30 1999-06-25 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines en tant que ligands specifiques du sous-type du recepteur de la dopamine

Country Status (5)

Country Link
EP (1) EP1089990A1 (fr)
JP (1) JP2002519346A (fr)
AU (1) AU4832699A (fr)
CA (1) CA2336150A1 (fr)
WO (1) WO2000000482A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1407552A (en) * 1973-04-02 1975-09-24 Science Union & Cie Disubstituted piperazines processes for their preparation and pharmaceutical compositions containing them
NZ187474A (en) * 1977-06-10 1981-03-16 Science Union & Cie 4-heterocyclyl-piperazine-i-carbodithioic acids and salts and pharmaceutical compositions thereof
DE3023227A1 (de) * 1980-06-21 1982-01-07 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von 2-chlor-benzthiazolen
US4510148A (en) * 1982-06-12 1985-04-09 Pfizer Inc. 2-Heterocyclic-1,3-bis(1H-1,2,4-triazol-1-yl)-propan-2-ols as antifungal agents
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
ES2062940B1 (es) * 1993-03-11 1995-06-16 Vita Invest Sa Agente gastrocinetico, proceso para su preparacion y composiciones farmaceuticas que lo contengan.
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
US5753595A (en) * 1995-08-31 1998-05-19 Fmc Corporation Herbicidal 3-(substituted benzoxazol-7-yl) and 3-(Substituted benzothiazol-7-yl)-1-substituted-6-trifluoromethyl-2 4-(1h 3h)pyrimidinediones
GEP20012389B (en) * 1996-05-29 2001-03-25 Warner Lambert Co Benzoxazinone Dopamine D4 Receptor Antagonists, Pharmaceutical Composition Containing the Same and Method for Treatment of Psychosis or Schizophrenia

Also Published As

Publication number Publication date
JP2002519346A (ja) 2002-07-02
EP1089990A1 (fr) 2001-04-11
WO2000000482A1 (fr) 2000-01-06
AU4832699A (en) 2000-01-17

Similar Documents

Publication Publication Date Title
US6284759B1 (en) 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands
AU703350B2 (en) Novel n-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
US6084098A (en) Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
WO1997031916A1 (fr) N-aminoalkyldibenzofurancarboxamides utilises comme ligands specifiques du sous-type du recepteur de la dopamine
EP0888332B1 (fr) N-Azacycloalkyldibenzothiophene carboxamides: ligands specifiques d'un sous-type de recepteur de la dopamine
US5688950A (en) Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
CA2345944A1 (fr) Derives de 2-piperazino -alkyl- aminobenzoazole: ligands specifiques du sous-type du recepteur de la dopamine
AU771199B2 (en) 1-phenyl-4-(1-(2-aryl)cyclopropyl) methylpiperazines: dopamine receptor ligands
US5922879A (en) N-aminoalkyl-2-anthraquinonecarboxamides: new dopamine receptor subtype specific ligands
CA2307905A1 (fr) 3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine
US6291463B1 (en) 1-(Benzothiazol-2-yl)-4-(1-phenylmethyl) piperazines: dopamine receptor subtype specific ligands
US6288230B1 (en) 2-(2, 3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands
US5703235A (en) N-Aminoalkyl-2-anthracenecarboxamides; new dopamine receptor subtype specific ligands
NZ337183A (en) 1-(isoquinolin-1-yl)-4-(1-phenylmethyl)piperazines; dopamine receptor subtype specific ligands useful for the treatment of psychotic disorders
CA2336150A1 (fr) 1-(benzothiazol-2-yl)-4-(1-phenylmethyl)piperazines en tant que ligands specifiques du sous-type du recepteur de la dopamine
US6100255A (en) 3-aminoalkylamino-2H-1,4-benzoxazines and 3-aminoalkylamino-2H-1,4-benzothiazines: dopamine receptor subtype specific ligands
US6008352A (en) 1-(isoquinolin-1-yl)-4-(1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands
CA2251795C (fr) Nouveaux n-aminoalkyl-1-biphenylenyl-2-carboxamides; nouveaux ligands specifiques de sous-types de recepteurs de la dopamine
US6166205A (en) 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
WO1999064396A1 (fr) 1-aryl-3-benzylaminopyrrolidine substitue: ligands specifiques aux sous-types des recepteurs de dopamine
WO2000012500A2 (fr) 2-aryl-4-[4-heteroaryl]piperazin-1-yl methylimidazoles: ligands pour le sous-type de recepteur d4 de la dopamine
WO2000018763A2 (fr) 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles; ligands specifiques du sous-type du recepteur de dopamine
MXPA99008086A (en) 1-(isoquinolin-1-yl)-4-(1-phenylmethyl)piperazines;dopamine receptor subtype specific ligands
CA2336089A1 (fr) Derives de 6-(4-arylalkylpiperazine-1-yl)benzodioxane et de 6-(4-arylalkylpiperazine-1-yl)chromane en tant que ligands specifique du sous-type du recepteur de la dopamine

Legal Events

Date Code Title Description
FZDE Dead